98%
921
2 minutes
20
Background: The concept of minimum clinically important difference (MCID) has been shown to be effective in spine surgery to differentiate between clinically insignificant and significant improvements as determined by the patient.
Objective: The MCID for spinal cord stimulation (SCS) to date has not been established. We sought to determine the MCID for SCS therapy for failed laminectomy syndromes.
Methods: Preoperative and 6-mo outcomes were assessed prospectively, including the Oswestry Disability Index (ODI), Beck Depression Inventory (BDI), and McGill and Visual Analog Survey questionnaires. Patients were asked: (1) are you satisfied with SCS therapy and (2) would you have the surgery again. Four methods of calculating the MCID were utilized.
Results: Forty-eight patients who underwent placement of an SCS between 2012 and 2014 were reviewed. The 4 calculation methods yielded a range of outcome scores (ODI 8.2-13.3, BDI 3.2-7, McGill 0.3-1.3, and Visual Analog Scale [VAS] 1.2-3.7). The maximum area under the curve was observed for the ODI, BDI, and VAS (0.73, 0.81, and 0.89, respectively), which signifies acceptable accuracy in distinguishing responders from nonresponders with the receiver operating characteristic method and suggests that VAS may be the most sensitive in determining meaningful change for the patient.
Conclusion: The MCID for SCS placement was calculated using 4 different methods. The results are similar to calculations for the MCID for many lumbar and cervical procedures done for pain. Our results suggest that an improvement of 1.2 to 3.7 points on the VAS scale and 8.2 to 13.3 points on the ODI is clinically meaningful to the patient. Further defining the MCID for SCS therapy will remain of utmost importance in order to justify the cost of the procedure.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/neuros/nyx153 | DOI Listing |
Adv Rehabil Sci Pract
June 2025
Department of Neurosurgery, National Neuroscience Institute, Tan Tock Seng Hospital, Singapore.
Objective: To present the rehabilitation considerations in prehabilitation and the rehabilitation phase post spinal cord stimulator implantation; and to evaluate the efficacy of synergistic combination of epidural spinal cord stimulation (SCS) with motor imagery, trunk rehabilitation, robotic and overground gait training in improving mobility in persons with sensorimotor complete spinal cord injury (SCI).
Design: A non-controlled before-after clinical trial.
Methods: Epidural spinal cord stimulators were implanted into 3 participants with complete thoracic SCI (Thoracic 4, Thoracic 2 and Thoracic 10 respectively).
Pain Physician
November 2024
Makous Research, LLC, Carlsbad, CA.
Neuromodulation
December 2024
Department of Neurosurgery, University of Arizona College of Medicine - Tucson, Tucson, AZ, USA. Electronic address:
Introduction: We examine ways intraoperative neuromonitoring during spinal cord stimulation (SCS) varies between a high-resolution investigational SCS (HR-SCS) paddle and a commercial paddle. Furthermore, the presence of evoked motor responses (eg, electromyography [EMG]) in painful regions during surgery is correlated to outcomes.
Materials And Methods: We used HR-SCS to assess EMG response from 18 patients (NCT05459324).
Healthcare (Basel)
March 2024
Department of Anesthesiology and Pain Medicine, The University of Kansas Medical Center, Kansas City, KS 66160, USA.
Spinal cord stimulation (SCS) is a well-established treatment for patients with chronic pain. With increasing healthcare costs, it is important to determine the benefits of SCS in healthcare utilization (HCU). This retrospective, single-center observational study involved 160 subjects who underwent implantation of a high-frequency (10 kHz) SCS device.
View Article and Find Full Text PDFPain Pract
June 2024
Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Background: Stiff person syndrome (SPS) is a rare neuroimmunological disorder characterized by rigidity and painful spasm primarily affecting the truncal and paraspinal musculature due to autoimmune-mediated neuronal hyperexcitability. Spinal cord stimulation (SCS) is an approved therapy for managing painful neuropathic conditions, including diabetic peripheral neuropathy and refractory angina pectoris. We describe the novel use of SCS for the treatment of spasm and rigidity in a 49-year-old man with seropositive stiff person syndrome (SPS).
View Article and Find Full Text PDF